Join
Live feed
·
INSIDERFilingvia Quantisnow
BioCryst Pharmaceuticals Inc. logo

CFO & Head of Corp Development Ghias Babar was granted 147,000 shares (SEC Form 4)

ByQuantisnow·Wall Street's wire, on your screen.
BCRX· BioCryst Pharmaceuticals Inc.
Health Care
Original source

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track BCRX (BioCryst Pharmaceuticals Inc.) and more on Quantisnow.